New dengue vaccine formula put to the test in phase 3 trial

NCT ID NCT07047521

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 20 times

Summary

This study compares a new version of the dengue vaccine to the current approved one in healthy adults aged 18 to 60 who have never had dengue. Participants receive two shots three months apart, and blood tests measure how well each vaccine triggers the immune system. The goal is to confirm the new formula works just as well as the current one.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DENGUE FEVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Emeritus Research Camberwell (Melbourne)

Camberwell, Victoria, 3124, Australia
Emeritus Research Sydney

Botany, New South Wales, 2019, Australia
Paratus Clinical Research Central Coast

Kanwal, New South Wales, 2259, Australia
Paratus Clinical Research Western Sydney

Blacktown, New South Wales, 2150, Australia
Veritus Research

Bayswater, Victoria, 3153, Australia

Conditions

Explore the condition pages connected to this study.

DENGUE FEVER